Answers are grounded in this paper and cite their sources.
(89)Zr-based imaging agents hold great promise as novel radio-tracers in nuclear medicine. However, insufficient stability of currently used radiometal complexes in vivo is a safety concern for clinical applications. We herein report the first octadentate bifunctional chelating agent for the development of (89)Zr-labelled (bio)conjugates with improved stability.
No takes yet. Share an insight, caveat, or question.
Patra et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: